Trials / Recruiting
RecruitingNCT07299825
A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
Phase 2 Study of A166 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With TOP1-ADCs
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the efficacy of A166 in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with TOP1 inhibitor Antibody-Drug Conjugates
Detailed description
This study will evaluate the efficacy of A166 in patients with HER2-positive unresectable or metastatic breast cancer previously treated with TOP1 inhibitor Antibody-Drug Conjugates. A166 will be administered every 3 weeks (Q3W) intravenous (IV) infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | A166 | intravenous(IV) infusion (Q3W) |
Timeline
- Start date
- 2024-09-20
- Primary completion
- 2027-09-20
- Completion
- 2027-12-31
- First posted
- 2025-12-23
- Last updated
- 2025-12-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07299825. Inclusion in this directory is not an endorsement.